Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P362. Survey from the Registry of the Italian Group of IBD on anti-TNF α therapy in IBD
Authors:

A. Redaelli1, S. Genise2, R. D'Incà3, F. Castiglione4, A. Orlando5, D. Valpiani6, R. D'Urso4, R. Pica7, M. Fortuna8, V. Annese2, on behalf of IG-IBD, 1Gastronterology, Monza, Italy, 2Gastroenterology, Florence, Italy, 3Gastroenterology, Padua, Italy, 4Gastroenterology, Naples, Italy, 5Gastroenterology, Palermo, Italy, 6Gastroenterology, Forlì, Italy, 7Gastroenterology, Rome, Italy, 8Gastroenterology, Negrer-Verona, Italy

P362

Agalactosyl IgG predicts therapeutic effect of anti-TNF agents in patients with Crohn's Disease

Authors:

M. Araki*, S. Shinzaki, H. Iijima, T. Yamaguchi, S. Kawai, S. Hiyama, T. Inoue, Y. Hayashi, K. Watabe, M. Tsujii, E. Miyoshi1, T. Takehara

Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, 2-2 Yamadaoka, Suita, Japan, 1Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine

P363.

Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re-induction regimens

Authors:

C. Felice, D. Pugliese, L. Guidi, M. Marzo, G. Andrisani, A. Papa, I. De Vitis, G.L. Rapaccini, A. Armuzzi, Catholic University, Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Rome, Italy

P363. Growing up with ileal pouch: Adult-patient controlled and coetaneous population-based long-term evaluation of patients undergoing pouch surgery in the developmental age
P363. Surgical management of ulcerative colitis during pregnancy
Authors:

I. Wilson1, J. Dench1, W. Garrett1, 1Medway Martime Hospital, Surgery, Gillingham, United Kingdom

P363. The IL-10 promoter polymorphisms is associated with both CD and UC in Tuscany population
P363

How did changes in medical protocols affect the length of resected ileum in Crohn's disease over the last decade?

Authors:

J. de Groof*1, T. Gardenbroek1, C. Buskens1, C. Ponsioen2, G. D'Haens2, W. Bemelman1

1Academic Medical Center, Surgery, Amsterdam, Netherlands, 2Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands

P364.

Resected fibrostenotic intestine from Crohn's disease patients express significant TNF in proliferative fibroblasts and in extracellular matrix

Authors:

R. Hundal1, S. Gui2, R. Panaccione1, M. Iacucci1, G. Kaplan1, J. Heatherington1, S. Liu2, H. Becker1, A. Ueno1, S. Ghosh1, 1University of Calgary, Division of Gastroenterology & IBD Clinic, Calgary, Canada, 2University of Calgary, Department of Pathology and Laboratory Medicine, Calgary, Canada

P364. Efficacy of anti‑TNF on severe postoperative endoscopic recurrence in Crohn's disease
P364. Genetic analysis of multiple inflammatory bowel disease susceptibility markers in the Lithuanian and Latvian patient populations
P364. Successful improvement of dysbiosis by fecal microbiota transplantation is not sufficient to induce clinical remission in chronic active ulcerative colitis
Authors:

P.K. Kump1, H.-P. Gröchenig2, S. Lackner3, S. Trajanovski3, G. Reicht4, K.M. Hoffmann5, H.H. Wenzl1, W. Petritsch1, G. Gorkiewicz6, C. Hoegenauer1, 1Medical University Graz, Gastroenterology and Hepatology, Graz, Austria, 2BHB Graz, Internal Medicine, St. Veith, Austria, 3Medical University Graz, Center of Medical Research, Graz, Austria, 4BHB Graz, Internal Medicine, Graz, Austria, 5University Hospital for Pediatric Diseases, Graz, Austria, 6University Graz, Institute of Pathology, Graz, Austria

P364

Immunization status in IBD patients -a single centre study in Southern Italy

Authors:

M. Ardesia*1, A. Ferrara1, A. Alibrandi2, W. Fries1

1University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, 2University of Messina, Department of Economical, Financial, Social, Environmental, Statistical and Territorial Sciences, Messina, Italy

P365.

Remission status and maintenance therapy outcomes in patients with mild-to-moderate ulcerative colitis (UC): Results from the MOMENTUM study

Authors:

G. D'Haens1, S. Inglis2, E. Magee3, P. Streck3, D. Solomon3, D. Rubin4, 1Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Shire, Clinical Development, Basingstoke, United Kingdom, 3Shire, Wayne, PA, United States, 4University of Chicago Medicine, Gastroenterology, Hepatology and Nutrition, Chicago, IL, United States

P365. Effectiveness of adalimumab in the treatment of perianal fistulas in patients with Crohn's disease naïve to anti-TNF: A multicenter study
P365. Genetic alterations of innate immune response in IBD: Planning and setting up a polymorphisms analysis method by multiplex PCR and minisequencing
P365. Smoking and the effect of its cessation on Crohn's disease progression and surgical rates
Authors:

I. Lawrance1, K. Murray2, B. Batman3, R. Gearry3, R. Grafton4, K. Krishnaprasad5, J. Andrews4, R. Prosser6, P. Bampton6, S. Cooke7, G. Mahy7, G. Radford-Smith8, A. Croft8, K. Hanigan8, 1Centre for Inflammatory Bowel diseases, Fremantle Hospital, University of Western Australia, Fremantle, Australia, 2Centre for Applied Statistics, University of Western Australia, Crawly, Australia, 3Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 4IBD Service, RAH Dept of Gastroenterology & Hepatology and School of Medicine at Royal Adelaide Hospital, Adelaide, SA, Australia, 5Inflammatory Bowel Disease Research Group, Queensland Institute of Medical Research, Brisbane, QLD, Australia, 6Dept of Gastroenterology and Hepatology, Flinders Medical Centre, Adelaide, SA, Australia, 7Gastroenterology, Townsville Hospital, Townsville, QLD, Australia, 8Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia

P365

Direct rescue treatment is justified in moderate flares of Ulcerative Colitis worsening with oral corticosteroid therapy

Authors:

J. Llaó*1, J. E. Naves2, A. Ruiz-Cerulla3, J. Gordillo4, M. Mañosa2, C. Arajol3, E. Cabre5, J. Guardiola3, E. Garcia-Planella4, E. Domenech2

1Hospital de la Santa Creu i de Sant Pau, Inflamatory bowel disease, Barcelona, Spain, 2Hospital Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 3Hospital de Bellvitge. Idibell, Gastroenterology, Barcelona, Spain, 4Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 5Hospital germans Trias i Pujol, Gastroenterology, Barcelona, Spain

P366.

Relevance of chromogranin A according to disease activity and medical treatment in IBD patients

Authors:

S. Vradelis1, A. Zissimopoulos2, M. Konialis3, D. Chadolias4, A. Bampali4, T. Konstantinidis5, E. Efremidou6, G. Kouklakis4, 1Democritus University of Thrace, University Hospital of Alexandroupolis, 2nd Department of Internal Medicine, Alexandroupolis, Greece, 2Democritus University of Thrace, Nuclear Medicine Department, Alexandroupolis, Greece, 3Democritus University of Thrace, Molecular Biology School, Alexandroupolis, Greece, 4Democritus University of Thrace, University Hospital of Alexandroupolis, Endoscopy Unit, Alexandroupolis, Greece, 5Democritus University of Thrace, Public Health Laboratory, Alexandroupolis, Greece, 6Democritus University of Thrace, University Hospital of Alexandroupolis, First Surgical Department, Alexandroupolis, Greece

P366. Enhanced recovery program applied to laparoscopic ileocecal resection for Crohn's disease
P366. rs1001179 CAT gene polymorphism could explain the inhibition of CAT expression in CD patients